Cyprotex Launches the Cloe® Select Blood to Plasma Ratio Assay
13 Oct 2009Cyprotex announces the introduction of a new experimental assay to evaluate the blood to plasma ratio of new chemical entities. The development of this service is a direct response to customer demand and, by offering this assay, Cyprotex will be extending its portfolio of Cloe® Select services.
Often the pharmacokinetics of a drug is evaluated by the analysis of drug concentrations in plasma rather than whole blood. This may be misleading if the concentrations of drug differ between plasma and red blood cells as a consequence of differential binding to a specific component in the blood. Blood to plasma ratio assists in determining the relevance of the plasma clearance and can also be used to understand potential haemotoxicity. Assessing the blood to plasma ratio is also one of several important parameters for predicting the pharmacokinetics of a drug at an early stage using in vitro data.
Dr Anthony D Baxter, the Chief Executive Officer of Cyprotex, comments on the launch ‘We are committed to providing a broad range of services for our customers to encourage them to use Cyprotex for all their ADME needs. Expanding our Cloe® Select portfolio of services is a key objective for us and will enable us to achieve this goal.’
Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. In combination, our Cloe® Screen, Cloe® Select and Cloe® Predict services offer an integrated solution for our customers’ experimental screening and prediction requirements.
Related Products
Request Quote for All Products
Cloe® Screen
Cyprotex Discovery LtdIn vitro ADME screening service Our in vitro ADME screening service offers a portfolio of assays for investigating: in vitro metabolism, in vitro permeability, solubility & physicochemical properties, toxicity, PK and bioanalysis. Cloe® Screen delivers consistent, accurate compound data with cost-efficiency that comes from a highly automated approach. • Highly reproducible, accurate data - validated and used by over 200 Pharmaceutical and Biotechnology companies. • Delivery of data for core in vitro ADME screening and physicochemical assays is within 10 working days to fit in with the make-test timelines in drug discovery. • Highly cost effective due to our emphasis on high throughput engineering. • Attention to good quality customer care, with highly trained Principal Scientists on hand to explain results and suggest the most appropriate experimental strategy. Cloe® Screen has passed evaluations by both large pharmaceutical and smaller biotechnology partners who now routinely use Cloe® Screen to support their drug discovery.
Cloe® Select
Cyprotex Discovery LtdBespoke ADME and DMPK experimental service Our Cloe® Select ADME and DMPK experimental service is designed to meet the requirements of later stage studies. Services include: in vitro metabolism, in vitro permeability, plasma protein binding, solubility, physicochemical properties, PK and bioanalysis. Cloe® Select offers the following benefits: • Flexibility - a portfolio of bespoke studies which can be customised to individual requirements. • Regulations - as with our Cloe® Screen ADME screens, our Cloe® Select service maintains and complies with regulatory guidelines providing constant confidence in the data received. • Results - a number of different reporting options are available from summary data to full written reports. • Consultancy - studies overseen by a single highly experienced and dedicated Principal Scientist who provides a high level of support and guidance prior to, during, and after the study.
Cloe® Predict
Cyprotex Discovery LtdCloe® PK - Pharmacokinetic prediction using PBPK modelling Cloe® PK is an innovative software system that uses PBPK modelling for pharmacokinetic prediction. By integrating physicochemical and ADME screening data, Cloe® PK can predict the levels and duration of drugs in blood, major tissues and organs. Human intestinal absorption model Cloe® Predict Human Intestinal Absorption Model is a reliable physiological model which uses a combination of solubility and Caco-2 permeability data for the prediction of human intestinal absorption. Auto QSAR and automation of laboratory workflow The Cyprotex Discovery Bus is a novel and powerful software platform designed to enhance efficiency in drug discovery by automating human decision making and information handling using intelligent workflow. Applications include auto QSAR and automation of laboratory workflow processes.